Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Boss Pressure To Vote GOP Was Also Big Pharma Tactic In 2000
Forbes
Sunday, October 28, 2012 - 11:49am
tags:
Analysts Objectivity in Coverage of the Obesity Space
Motley Fool
Sunday, October 28, 2012 - 11:43am
tags:
obesity, weight loss, Orexigen, Arena Pharmaceuticals
Vertex Pharma Third Quarter Earnings Sneak Peek
Wall Street Cheat Street
Sunday, October 28, 2012 - 11:42am
tags:
Vertex Pharmaceuticals, earnings
A Looming Threat for Arena and VIVUS
Motley Fool
Sunday, October 28, 2012 - 11:41am
tags:
Arena Pharmaceuticals, Vivus, Orexigen, weight loss, obesity
Drug Shortage, Aging Baby Boomers Create A Great Opportunity For Teva
Seeking Alpha
Sunday, October 28, 2012 - 11:39am
tags:
Teva Pharmaceuticals
Eyeing a Sandbagged Guidance
Motley Fool
Sunday, October 28, 2012 - 11:37am
tags:
Regeneron
This Week in Biotech
Motley Fool
Sunday, October 28, 2012 - 11:37am
tags:
Columbia Laboratories, United Therapeutics, Watson Pharmaceuticals, Regeneron, Alexion
New Developments In Lipids To Watch Closely
Seeking Alpha
Sunday, October 28, 2012 - 11:31am
tags:
Lpath, Pfizer, iSONEP, Asonept, macular degeneration, multiple sclerosis, MS, Regeneron, Roche, Bayer, Sanofi, Valeant Pharmaceuticals, GSK
Agenus' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Seeking Alpha
Sunday, October 28, 2012 - 11:25am
tags:
Agenus, earnings
Forest Laboratories, Inc. Announces Settlement Agreement with Hetero Labs Ltd. in BYSTOLIC® Patent Litigation
Business Wire
Saturday, October 27, 2012 - 12:25pm
tags:
Forrest, Hetero Labs, Bystolic, generics, patents, lawsuits
Valeant Pharmaceuticals Price Target Lowered to $67.00 at Paradigm Capital (VRX)
Zolmax
Saturday, October 27, 2012 - 12:24pm
tags:
Valeant Pharmaceuticals
Watson Receives FDA Approval for Generic Actos®
Equities.com
Saturday, October 27, 2012 - 12:23pm
tags:
Watson Pharmaceuticals, Actos, generics
KV files new 337 complaint regarding hydroxyprogesterone caproate and products containing same
lexology
Saturday, October 27, 2012 - 12:22pm
tags:
KV Pharmaceutical
Boehringer Ingelheim to pay $95M in settlement
Wilkes Barr Times-Leader, PA
Saturday, October 27, 2012 - 12:21pm
tags:
off label, legal
Bristol-Myers Squibb and Eli Lilly: The Patent Cliff Strikes Back
Wall Street Cheat Street
Saturday, October 27, 2012 - 12:19pm
tags:
Bristol-Myers Squibb, Eli Lilly
Abbott: Cash In On This Big Pharma's Recent Pullback Now
Seeking Alpha
Saturday, October 27, 2012 - 12:17pm
tags:
Abbott Laboratories
Merck 3Q profit up 2 pct despite sales decline
Yahoo/AP
Saturday, October 27, 2012 - 11:42am
tags:
Merck, earnings
One Reason Novartis is Expected to Overtake Pfizer in Revenue: its Generics Business
Forbes
Saturday, October 27, 2012 - 11:41am
tags:
Novartis, Pfizer
Pharmaceutical Stocks Are All-of-a-Sudden Hot Again: Read About Drugs and Dividends
Forbes
Saturday, October 27, 2012 - 11:40am
tags:
Merck, Eli Lilly, Abbott Laboratories, Novartis, Pfizer
Pharma Drug Wars: Two Winners and One Loser
Wall Street Cheat Street
Saturday, October 27, 2012 - 11:39am
tags:
Novartis, AstraZeneca, Sanofi

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.